Related Experiment Video

Updated: May 25, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

Diastolic heart failure in dialysis patients: mechanisms, diagnostic approach, and treatment

Roberto Pecoits-Filho1, Sérgio Bucharles, Silvio H Barberato

  • 1Center for Health and Biological Sciences, Pontificia Universidade Católica do Paraná, Curitiba, Brazil.

Seminars in Dialysis
|January 26, 2012
PubMed

Insights

Diastolic heart failure (DHF), common in chronic kidney disease (CKD) patients, predicts death. This review covers DHF mechanisms, presentation, impact, and interventions relevant to CKD.

Area of Science:

  • Cardiology
  • Nephrology
  • Internal Medicine

Background:

  • Heart failure (HF) is prevalent in the general population and a significant cause of morbidity and mortality in chronic kidney disease (CKD) patients.
  • Risk factors for HF, including diabetes, obesity, and hypertension, are common in CKD.
  • Diastolic heart failure (DHF), or HF with preserved ejection fraction, is increasingly recognized and particularly impactful in CKD.

Purpose of the Study:

  • To review current knowledge on DHF in CKD patients.
  • To explore mechanisms, clinical presentation, and impact of DHF in this population.
  • To discuss potential interventions for DHF, drawing from CKD and general population evidence.

Main Methods:

  • Literature review of existing studies on DHF.
  • Analysis of evidence from both CKD and general populations.
  • Synthesis of information on pathophysiology, clinical aspects, and therapeutic strategies.

Main Results:

  • DHF is a strong predictor of mortality in CKD patients.
  • HF with normal ejection fraction is common in CKD, including those on hemodialysis.
  • Understanding DHF mechanisms and presentation is crucial for managing CKD patients.

Conclusions:

  • DHF represents a significant clinical challenge in chronic kidney disease.
  • Further research into DHF mechanisms and targeted interventions is warranted for CKD patients.
  • Effective management of DHF may improve outcomes in the CKD population.

More Related Videos

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

Related Concept Videos

Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...